Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

featured

Published in Advanced Prostate Cancer and

Journal Scan / Research · February 11, 2021

Prostate-Only vs Whole-Pelvic Radiation Therapy in High-Risk and Very High–Risk Prostate Cancer

Journal of Clinical Oncology

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Not a member?

Join for free

Disclosure statements are available on the authors' profiles:

Timothy Masterson MD, FACS

Journal of Clinical Oncology

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial

J. Clin. Oncol 2021 Jan 26;[EPub Ahead of Print], V Murthy, P Maitre, S Kannan, G Panigrahi, R Krishnatry, G Bakshi, G Prakash, M Pal, S Menon, R Phurailatpam, S Mokal, D Chaurasiya, P Popat, N Sable, A Agarwal, V Rangarajan, A Joshi, V Noronha, K Prabhash, U Mahantshetty

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Advanced Prostate Cancer

Prostate-Only vs Whole-Pelvic Radiation Therapy in High-Risk and Very High–Risk Prostate Cancer

Additional Info

Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial

Further Reading

2022 Top Story in Advanced Prostate Cancer: Efficacy of Abiraterone and Prednisolone Alone or With Enzalutamide in High-Risk Nonmetastatic Prostate Cancer

Impact of Salvage Radiotherapy Initiation at PSA ≤0.5 ng/mL on Survival Outcomes in Patients With Relapsed Prostate Cancer After Prostatectomy

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

PSMA-PET as a Predictive and Prognostic Tool in Patients Administered [177Lu]Lu-PSMA-617 vs Cabazitaxel for Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer Aggressiveness and Financial Toxicity in Patients With Prostate Cancer

VISION Trial Analysis of Time-to-Event Endpoints Associated With Radioligand Therapy

Androgen Annihilation in Patients With High-Risk, Biochemically Relapsed Prostate Cancer

Gene-Based Confirmatory Germline Testing Following Tumor-Only Sequencing of Prostate Cancer

Duration of Androgen Deprivation Therapy With Post-Operative Radiotherapy for Prostate Cancer

Abiraterone Plus Enzalutamide for Metastatic Hormone Sensitive Prostate Cancer

SPOP Mutations as a Biomarker for Selecting Androgen Receptor Axis–Targeted Therapy in Patients With mCSPC

Recently Updated